Intec Pharma(NTEC)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/NTEC/m 发布时间：2021-03-24

Roger J. Pomerantz，2014年6月起担任本公司总裁和首席执行官；2013年11月起担任董事长。2014年7月起担任Flagship Ventures（一家早期合资公司）高级合伙人。2011年1月-2013年9月，在一家医药公司- Merck & Co., Inc.或Merck担任授权和收购全球负责人、高级副总裁，监管Merck Research Laboratories的授权和收购事务，以及Merck的研发部门。2010年2月-2013年2月，在Merck担任感染疾病全球主管和高级副总裁，监管抗生素、抗病毒剂、抗真菌剂和抗寄生虫剂药物开发和发现。2005年8月-2010年2月，在一家专注于感染性疾病治疗的医药公司- Tibotec Pharmaceuticals, Inc.（现为Janssen Therapeutics）担任总裁。他曾开发了8种通过核准的艾滋病、丙型肝炎和肺结核感染性疾病药物。他目前还在一家生物科技公司- Contrafect Corporation董事会任职。他持有The Johns Hopkins大学的生物化学学士学位和The Johns Hopkins医学院的医学博士学位。

Roger J. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to December 2019 Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics, Inc., a biotechnology company, and as its President and Chief Executive Officer from June 2014 to January 2019. From 2011 to 2013 he was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz serves as Chairman of the board of directors of the public company Collplant Biotechnologies, Inc., a board member of the public company Intec Therapeutics, Inc., Chairman of the board of directors of the private company Silicon Therapeutics Inc. and a member of the board of the private company X-VAX Technology, Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed 12 drugs approved world-wide in important diseases, including HIV, HCV, CMV, Clostridium difficile and tuberculosis. Roger J. Pomerantz，2014年6月起担任本公司总裁和首席执行官；2013年11月起担任董事长。2014年7月起担任Flagship Ventures（一家早期合资公司）高级合伙人。2011年1月-2013年9月，在一家医药公司- Merck & Co., Inc.或Merck担任授权和收购全球负责人、高级副总裁，监管Merck Research Laboratories的授权和收购事务，以及Merck的研发部门。2010年2月-2013年2月，在Merck担任感染疾病全球主管和高级副总裁，监管抗生素、抗病毒剂、抗真菌剂和抗寄生虫剂药物开发和发现。2005年8月-2010年2月，在一家专注于感染性疾病治疗的医药公司- Tibotec Pharmaceuticals, Inc.（现为Janssen Therapeutics）担任总裁。他曾开发了8种通过核准的艾滋病、丙型肝炎和肺结核感染性疾病药物。他目前还在一家生物科技公司- Contrafect Corporation董事会任职。他持有The Johns Hopkins大学的生物化学学士学位和The Johns Hopkins医学院的医学博士学位。 Roger J. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to December 2019 Dr. Pomerantz served as Chairman of the board of directors of Seres Therapeutics, Inc., a biotechnology company, and as its President and Chief Executive Officer from June 2014 to January 2019. From 2011 to 2013 he was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Dr. Pomerantz serves as Chairman of the board of directors of the public company Collplant Biotechnologies, Inc., a board member of the public company Intec Therapeutics, Inc., Chairman of the board of directors of the private company Silicon Therapeutics Inc. and a member of the board of the private company X-VAX Technology, Inc. Dr. Pomerantz received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He received post-graduate training at the Massachusetts General Hospital, Harvard Medical School and M.I.T. Dr. Pomerantz is Board Certified in both Internal Medicine and Infectious Diseases. He was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed 12 drugs approved world-wide in important diseases, including HIV, HCV, CMV, Clostridium difficile and tuberculosis.